Regarding the contract, covered membership count, revenue per member, utilization, and product costs are all meeting our expectations. As for Q1 financial results, first quarter revenue of $819.8 million grew 5.4% versus the prior year quarter and exceeded the midpoint of our guidance range by approximately $22 million. On an organic basis, adjusting for the impact of acquisitions and dispositions, we delivered 9.1% year-over-year growth. Of that, about 500 basis points came from the new capitated contract.
The other 400 basis points came from the base business, with each of our four segments delivering positive organic growth in the quarter. Sleep Health net revenue of $358.5 million grew 13.3% versus the prior year, and PAP new starts set another new record. We anticipate that as accumulating evidence highlights the significance of sleep in overall health, there will be corresponding increase in demand for therapies aimed at improving sleep quality. Despite a very mild flu season, Respiratory Health net revenue of $178.1 million grew 7.6% versus the prior year, and oxygen new starts grew 12.8%.
Diabetes Health net revenue of $142.2 million grew 2.4% versus the prior year. Wellness at Home net revenue of $141 million declined 10.3% on a reported basis, reflecting $35.8 million of disposed revenue from non-core assets exited during 2025. Over the past two years, we have carefully pruned our portfolio to product categories that support growth in our Sleep and Respiratory Health segments. After adjusting for these dispositions, Wellness at Home delivered 11% organic growth.
| Metric | Period | Current guidance |
|---|---|---|
| — | — | — |
| — | — | — |
| — | — | — |
| — | — | — |
| — | — | — |
| — | — | — |
| — | — | — |
| — | — | — |
| Metric | YoY | Note |
|---|---|---|
| — | — | — |
| — | — | — |
| — | — | — |
| — | — | — |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |